Compare RILY & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RILY | CUVL |
|---|---|---|
| Founded | 1973 | N/A |
| Country | United States | Australia |
| Employees | N/A | 16 |
| Industry | Investment Managers | Miscellaneous |
| Sector | Finance | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 349.8M | 374.2M |
| IPO Year | 2014 | N/A |
| Metric | RILY | CUVL |
|---|---|---|
| Price | $6.79 | $5.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 468.6K | 19.7K |
| Earning Date | 03-31-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 138.49 | N/A |
| EPS | ★ 6.47 | N/A |
| Revenue | ★ $967,599,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.09 | ★ N/A |
| Revenue Growth | ★ 15.38 | N/A |
| 52 Week Low | $3.64 | $5.95 |
| 52 Week High | $11.24 | $8.20 |
| Indicator | RILY | CUVL |
|---|---|---|
| Relative Strength Index (RSI) | 43.44 | 37.95 |
| Support Level | $6.45 | N/A |
| Resistance Level | $7.83 | $7.04 |
| Average True Range (ATR) | 0.24 | 0.45 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 35.81 | 1.30 |
BRC Group Holdings Inc is a diversified holding company offering a platform of businesses, including financial services (with complementary banking and wealth management businesses), telecom, retail, and investments in equity, debt, and venture capital. It serves retail, corporate, capital providers, and individual customers across different business lines. The Group reports its activities in seven reportable business segments: Capital Markets, Wealth Management, Lingo, magicJack, Marconi Wireless, UOL, and Consumer Products. Maximum revenue is generated from the Consumer Products segment, which offers mobile computing accessories and home furnishing products. Geographically, the Group derives its revenue from North America.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.